Accelr8 Eyes HAI Test Market As It Gets US Patent Allowance on BACcel System | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
As a growing number of firms line up to challenge Cepheid’s and Becton Dickinson’s molecular tests for hospital-acquired infections, Accelr8 is developing a single-cell test system that could potentially supply a physician with more critical information within a few hours.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.